Also, improvement of hepatic steatosis by CD36 downregulation in a murine model of NAFLD was reported for another FXR agonist, GW4064 (Ma et al., 2013), which is also an inhibitor in our phenotypic model, with similar potency to OCA, albeit lower efficacy (data not shown). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.